Literature DB >> 18999945

Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States.

Mitesh S Patel1, Achamyeleh Gebremariam, Matthew M Davis.   

Abstract

OBJECTIVE: With childhood varicella vaccination in the United States have come concerns that the incidence of herpes zoster may increase, because of diminishing natural exposure to varicella and consequent reactivation of latent varicella zoster virus. We wanted to estimate the rate of herpes zoster-related hospitalizations and the associated hospital charges before and during the promotion of varicella vaccination in the United States.
DESIGN: A retrospective study of patients from the Nationwide Inpatient Sample for the years 1993-2004 who were hospitalized due to herpes zoster infection.
METHODS: We searched for diagnoses of herpes zoster (using the International Classification of Diseases, Ninth Revision, Clinical Modification codes starting with 053) in all 15 diagnostic-code fields included for hospital discharges in the Nationwide Inpatient Sample during 1993-2004. We designed our analysis to examine the rates of severe illness due to herpes zoster that resulted in hospitalization, as measured by the rates of herpes zoster-related hospital discharges (HZHDs). The annual population-adjusted rate of HZHDs (per 10,000 US population) and the annual inflation-adjusted total charges for HZHDs were the primary outcomes. Secondary outcomes included mean charges for HZHDs and the distribution of total charges for HZHDs by expected primary payer. Varicella-related hospital discharges (VRHDs) were identified by use of similar diagnosis-based methods, which were described in our previous study.
RESULTS: Population-adjusted rates of HZHDs did not change significantly from the prevaccination years (1993-1995) through the initial 5 years of the varicella vaccination period. Beginning in 2001, however, the rate of HZHDs overall began to increase, and by 2004 the overall rate was 2.5 HZHDs (95% confidence interval, 2.38-2.62) per 10,000 US population, significantly higher than any of the rates calculated during the years prior to 2002. Hospital charges for HZHDs overall increased by more than $700 million annually by 2004; in particular, we found that the herpes zoster vaccine-eligible population (ie, persons aged 60 years or older) accounted for 74% of the total annual hospital charges in 2004. The annual rate of VRHDs and the associated hospital charges decreased significantly from 1993 through 2004, but the decrease in hospitalizations and charges for VRHDs was less than the increase in hospitalizations and charges for HZHDs.
CONCLUSIONS: As the rates of VRHDs and the associated charges have decreased, there has been a significant increase in HZHDs and associated charges, disproportionately among older adults. Herpes zoster vaccine may mitigate these trends for HZHDs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18999945     DOI: 10.1086/591975

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  19 in total

Review 1.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 2.  Evaluation of the economic burden of Herpes Zoster (HZ) infection.

Authors:  Donatella Panatto; Nicola Luigi Bragazzi; Emanuela Rizzitelli; Paolo Bonanni; Sara Boccalini; Giancarlo Icardi; Roberto Gasparini; Daniela Amicizia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study.

Authors:  Anita E Heywood; Han Wang; Kristine K Macartney; Peter McIntyre
Journal:  Bull World Health Organ       Date:  2014-06-13       Impact factor: 9.408

4.  Increasing hospitalizations in inflammatory bowel disease among children in the United States, 1988-2011.

Authors:  Kelly C Sandberg; Matthew M Davis; Achamyeleh Gebremariam; Jeremy Adler
Journal:  Inflamm Bowel Dis       Date:  2014-10       Impact factor: 5.325

5.  Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997-2011.

Authors:  Kelly C Sandberg; Matthew M Davis; Achamyeleh Gebremariam; Jeremy Adler
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-04       Impact factor: 2.839

Review 6.  Varicella vaccination - the global experience.

Authors:  Peter Wutzler; Paolo Bonanni; Margaret Burgess; Anne Gershon; Marco Aurélio Sáfadi; Giacomo Casabona
Journal:  Expert Rev Vaccines       Date:  2017-07-13       Impact factor: 5.217

7.  Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.

Authors:  Alies van Lier; Albert Jan van Hoek; Wim Opstelten; Hein J Boot; Hester E de Melker
Journal:  BMC Health Serv Res       Date:  2010-08-13       Impact factor: 2.655

8.  Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella.

Authors:  Samir S Shah; Sarah M Wood; Xiquan Luan; Adam J Ratner
Journal:  Pediatr Infect Dis J       Date:  2010-03       Impact factor: 2.129

9.  Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Authors:  Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

Review 10.  Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review.

Authors:  Benson Ogunjimi; Pierre Van Damme; Philippe Beutels
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.